Early diagnosis of lung cancer is thought to be important for improving outcomes. Survival is better for patients diagnosed at an early stage because they are more likely to be suitable for receipt of curative treatment ([@bib32]). Delays between the onset of cancer symptoms and receipt of treatment could result in potentially resectable tumours becoming inoperable, and this may contribute to the poorer survival of UK cancer patients compared with that found in other European countries ([@bib32]).

In the United Kingdom, there are a number of different routes to diagnosis. Three of these diagnostic pathways reflect the urgency of the referral (emergency presentation at hospital or via the GP, urgent 2-week GP referral and other GP referral; [@bib11]). Theoretical models of the pathway from first symptom to cancer treatment identify key diagnostic (including referral) and treatment intervals, and related healthcare system (primary and secondary care) settings ([@bib16]; [@bib35]). An early model of cancer delay, the Anderson model, attributed the majority of delay to patient factors ([@bib3]). The model has been updated to also consider tumour and healthcare system factors ([@bib35]), as these are likely to make important contributions to the time to diagnosis and treatment.

Three intervals are currently the subject of performance management within the NHS in England. Since 2000, urgent referrals for suspected cancer have been required to have a first hospital appointment (FHA) within 14 days from the date of GP referral (referral interval). Since 2005, target intervals of 62 days from the date of urgent GP referral to first treatment and 31 days from diagnosis (decision-to-treat) to first treatment (treatment intervals) have been in place ([@bib9]). Interim diagnostic interval targets of 31 days from GP referral and 17 days from FHA can be inferred ([Figure 1](#fig1){ref-type="fig"}).

Although research has explored factors that might influence the time spent within pathway intervals for breast and colorectal cancer ([@bib30]; [@bib22]), there is little definitive evidence on the factors that are important for lung cancer. In a review of potential reasons for delay in lung cancer care (14 studies), variables including stage, co-morbidity, atypical symptoms, income, age, sex, rural residence and distance to healthcare were examined ([@bib29]). The authors were unable to draw any clear conclusions as they reported that the quality of included studies was poor. The majority of studies considered only single factors and did not take into account potential confounders such as age, stage, histology and co-morbidity ([@bib29]).

In this study, cancer registry, Hospital Episode Statistics (HES) and lung cancer audit (LUCADA) data sets were linked to investigate the factors (socioeconomic position (SEP), age, sex, histology, co-morbidity, year of diagnosis, stage and performance status (PS)) that may influence the likelihood of post-primary care referral, diagnosis and treatment within target times.

Materials and methods
=====================

Data sources and linkage
------------------------

We analysed a linked data set reported previously ([@bib15]). Data for 29 385 patients with a primary diagnosis of lung cancer (ICD10 C33 and C34), diagnosed between 1 January 2006 and 31 December 2010, were obtained from the Northern and Yorkshire Cancer Registry and Information Centre ([@bib28]). Of these, 652 had tumour registration based on death certification only and so were excluded from analyses, leaving an eligible cohort of 28 733.

Data on SEP, age, sex, histology, year of diagnosis, GP referral date, FHA date, diagnosis date, treatment dates and details of receipt of treatment (surgery, chemotherapy and radiotherapy) were obtained from the registry data. Co-morbidity data were obtained from HES and used to calculate a co-morbidity score. Data on stage and PS were obtained from the national LUCADA, a non-mandatory register of clinical information on patients diagnosed with lung cancer comprising a subset of registry patients (66% nationally in 2006, increasing to 93% in 2010; [@bib26]).

Records were allocated a unique, randomly generated, key number, derived from the NHS number by NYCRIS. Data from the three data sources were anonymised and supplied by NYCRIS. The HES and LUCADA data were then linked to the registry data using this key.

Variables of interest
---------------------

SEP was measured using the income domain of the Index of Multiple Deprivation (IMD; [@bib17]), grouped into quintiles for analysis. This is an area-based measure of SEP, where Q5 is the most deprived and Q1 the least deprived. Age at diagnosis was categorised into four groups for analysis: \<60, 60--69, 70--79 and 80+ years. Year of diagnosis was included to examine system changes over time.

Histology was classified as confirmed non-small-cell lung cancer (NSCLC), including adenocarcinoma, large-cell carcinoma, non-small-cell carcinoma and squamous cell carcinoma subtypes; small-cell lung cancer (SCLC); and other histology (including unspecified carcinoma, neoplasm, other specified carcinomas and carcinoid tumours).

A weighted co-morbidity score was calculated by NYCRIS using the Charlson co-morbidity index (CCI; [@bib6]) a validated instrument used previously to determine co-morbidity in cancer patients. No HES-linked data were available for patients diagnosed in 2009--2010 as, due to national problems in calculating the co-morbidity score, there was a time lag in data availability. Patients without a CCI score were split into those who did and did not have a HES linkage. CCI score was categorised as 0, 1--2, 3+, missing (HES-linked data available but no CCI score recorded) or unavailable (no HES-linked data available).

Stage was assigned using the TNM staging system and categorised as I, II, III, IV or missing ([@bib33]). PS is a measure of general well-being for cancer patients, assessed on a scale of 0 (asymptomatic) to 4 (bedridden) using the Eastern Co-operative Group PS scale ([@bib27]) and was categorised as 0, 1--2, 3--4 or missing. Stage and PS data were entered into LUCADA by trusts participating in the audit.

[Table 1](#tbl1){ref-type="table"} shows the referral and treatment intervals included in this study ([@bib14]), alongside target times for these. The referral interval was categorised as: GP referral date to FHA ⩽14 days (within target), GP referral \>14 days and no GP referral. Interim diagnostic intervals and the target times that can be inferred are also shown in [Table 1](#tbl1){ref-type="table"}. These were calculated as follows: GP referral to diagnosis (62−31=31 days) and FHA to diagnosis (31−14=17 days).

Between 2006 and 2009, date of diagnosis was determined by cancer registries as the first time the tumour was identified either by imaging or histology in the case notes. In 2010, UK Association of Cancer Registry guidance was followed. The guidance uses a priority hierarchy with six categories to determine date of diagnosis; the date of histological or cytological confirmation of malignancy (which can be derived from three different hierarchical time points); date of hospital admission; and down to, with lowest priority, date of death if cancer is only identified at autopsy ([@bib36]).

Analysis
--------

Median referral, diagnostic and treatment times, with inter-quartile range (IQR), were calculated for each time interval. The number and percentage of patients referred, diagnosed and treated within target were also calculated for each time interval, by each included variable. Differences in the likelihood of referral, diagnosis and treatment within target by SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage and PS were explored using logistic regression models mutually adjusted for all co-variables. As the aim was to explore which factors might be important for time spent within each interval, the variable selection procedure was based on an underlying conceptual framework rather than on formal stepwise methods ([@bib19]). Variables were selected for inclusion if they had previously been identified as potentially important. Referral interval was adjusted for in the models for the FHA to diagnosis and diagnosis to treatment intervals. Type of first treatment was included in the models for treatment intervals. Receipt of treatment was included in the models for diagnostic intervals.

Patients were eligible for inclusion within an interval if they had a date recorded for the interval start and end point. Records were excluded from analyses if they had a negative interval for any time period, for example, if they had a GP referral date later than diagnosis date, as this was likely to be a data entry error. Records were included if they had 0 time between dates (for example, treatment date was recorded on the same day as date of diagnosis). To include these records in the analysis, 0 time intervals were recoded as 0.1. Analysis was also restricted to those cases with interval dates within 1 year of the previous interval end point.

Odds ratios (ORs) with 95% confidence intervals (CIs) for the likelihood of receipt of referral, diagnosis and treatment within target for each variable were reported. Likelihood ratio tests were used to determine the overall significance of each categorical variable. Analysis was carried out in Stata v12.0 (StataCorp, College Station, TX, USA).

Results
=======

Data and descriptive statistics
-------------------------------

Of the full cohort (28 733), 7769 (27.0%) had stage and 8885 (30.9%) had a PS score recorded in LUCADA, and 18 650 (64.9%) had a linked HES record, of whom 8475 (29.5%) had a CCI score recorded. All 28 733 patients had a date of diagnosis, 28 704 (99.9%) had FHA date recorded, 15 452 (53.8%) had a GP referral date and 15 373 (53.5%) received any treatment within 1 year of diagnosis. Once patients with negative intervals and intervals longer than 1 year were excluded, 14 507 patients had GP referral and FHA dates recorded, and also GP referral and diagnosis dates; 27 555 had FHA and diagnosis dates; 14 692 had diagnosis and treatment dates; and 9542 had GP referral and treatment dates. The demographic and clinical characteristics of the patients included in each analysis are shown in columns 1--4 of [Tables 2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"}.

Referral interval: likelihood of FHA within 14 days from GP referral
--------------------------------------------------------------------

Median time from GP referral to FHA was 10 days (IQR 6--17), *n*=14 507. Of those referred by their GP, 70.4% had FHA within the 14-day target from GP referral. The data set included both urgent and non-urgent referrals.

Greater deprivation was associated with a lower likelihood of FHA within 14 days of GP referral in the multivariable analysis (OR=0.83, CI 0.73--0.94), but the lowest likelihood was for those in the middle SEP groups. No simple pattern by age emerged. Late-stage cancer, SCLC, poor PS and referral post-2006 were associated with increased likelihood of FHA within 14 days of referral, but sex and CCI score were not ([Table 2](#tbl2){ref-type="table"}).

Diagnostic interval: likelihood of diagnosis within 31 days from GP referral
----------------------------------------------------------------------------

In those patients with GP referral and diagnosis dates (*n*=14 507), median time from GP referral to diagnosis was 13 days (IQR 7--24) and 82.6% were diagnosed within the 31-day target.

Neither SEP nor age was associated with likelihood of diagnosis within 31 days of GP referral overall, although those in the middle SEP groups had significantly lower likelihood of diagnosis within 31 days ([Table 3](#tbl3){ref-type="table"}). Patients with poorer PS, later-stage cancer and those with SCLC had an increased likelihood of diagnosis within 31 days of GP referral. Those diagnosed in 2007--2009 had a higher likelihood of diagnosis within 31 days.

Diagnostic interval: likelihood of diagnosis within 17 days from FHA
--------------------------------------------------------------------

In those patients with FHA and diagnosis dates (*n*=27 555), median time from FHA to diagnosis was 0 days (IQR 0--0) and 91.4% of patients were diagnosed within 17 days.

Neither SEP nor age was associated with likelihood of diagnosis within 17 days of FHA ([Table 3](#tbl3){ref-type="table"}). Patients with poorer PS, later-stage cancer and those with SCLC had an increased likelihood of timely diagnosis. Those diagnosed in 2007--2009 had a higher likelihood of timely diagnosis.

Treatment interval: likelihood of treatment within 31 days from diagnosis
-------------------------------------------------------------------------

Of the 14 692 patients who were treated within 1 year, median time to treatment was 35 days (IQR 21--55) and 43.1% (6333) were treated within the 31-day target time from diagnosis ([Table 4](#tbl4){ref-type="table"}).

There was no association between SEP and likelihood of treatment within 31 days of diagnosis (*P*=0.41). Patients diagnosed with SCLC were significantly more likely to receive treatment within target compared with those diagnosed with NSCLC (OR=4.53, CI 4.06--5.04). Older patients were significantly less likely to receive treatment within the 31-day target (OR=0.79, CI 0.69--0.91).

Those receiving surgery were less likely to receive treatment within target times compared with those receiving chemotherapy. Those with poor PS and later-stage cancer were more likely to receive treatment within target.

Treatment interval: likelihood of treatment within 62 days from GP referral
---------------------------------------------------------------------------

Of the 9542 patients who were referred by their GP and had treatment, median time from GP referral to first treatment date was 56 days (IQR 39--79) and 61.2% of those who received treatment were treated within 62 days ([Table 4](#tbl4){ref-type="table"}), although we had no details of how many of these were urgent referrals. An overall association between SEP and likelihood of starting treatment within the target time was found (*P*=0.04), with those in the middle SEP groups significantly less likely to start treatment within 62 days.

Early-stage patients, older patients and those receiving surgery were significantly less likely to start treatment within 62 days, whereas late-stage patients, those with poor PS and those receiving chemotherapy, were more likely to do so. The likelihood of receiving treatment within guidelines significantly improved over time.

Discussion
==========

Principal findings
------------------

To our knowledge, this is the first study to examine factors associated with referral, diagnosis and treatment within target for lung cancer in England. Generally, those with SCLC, those with poorer PS, patients diagnosed in more recent years, and those with more advanced stage cancer were more likely to have post-primary care referral, diagnosis and treatment within target. Older patients were less likely to receive first treatment within the target time. Patients undergoing surgery and radiotherapy as their first treatment were less likely to receive treatment within target than those receiving chemotherapy as a first treatment.

Socioeconomic inequalities in the time from GP referral to FHA, diagnosis and treatment were found, but were not present for the interim intervals from FHA to diagnosis or from diagnosis to treatment. This would suggest that SEP inequalities originate from the GP referral to FHA interval. However, a linear trend was not seen. Patients in the middle SEP groups were less likely to receive FHA, diagnosis or treatment within target, compared with the least deprived SEP group, but this was not consistently observed for the most deprived SEP group.

Strengths and weaknesses
------------------------

The use of multiple data set linkage is a strength of this study. There are good data completeness and validity within the registry data set. Linkage to HES and LUCADA data allowed inclusion of a wide range of factors that are potentially important for post-primary care referral, diagnosis and treatment within target for lung cancer. Previous studies examining lung cancer delay mainly conducted only univariable analyses and did not include potential confounders such as age, stage, histology and co-morbidity ([@bib29]). We were able to take all these factors, as well as others such as PS and SEP, into account. However, a lack of concordance in recording of data between registry and LUCADA data sets has been found ([@bib31]).

The type of referral route may influence time to diagnosis and treatment. Nearly half of the patients (46%) did not have a GP referral date recorded, but it was not possible to determine from our data how many of these patients had been referred via a different route, how many had a GP referral but the date was not recorded or which were urgent GP referrals. A large study examining routes to diagnosis also found that low numbers (41%) of lung cancer patients were referred via their GP (as urgent or non-urgent referrals; [@bib11]). Those who did have a GP date had longer time to treatment than those who did not. This reflects previous findings ([@bib1]) and suggests that those without a GP referral date may be presenting as emergency cases and thus receive more urgent investigation and treatment.

We examined the interim diagnostic interval from FHA to diagnosis. However, the FHA and diagnosis date often appeared to be recorded as the same date, which may be due to variability in the recording of date of diagnosis in the registry data set. A number of different dates can be used to determine date of diagnosis. Inconsistent application of the rules could affect calculation of the diagnostic and treatment intervals and thus introduce error, although there is no evidence to suggest bias in recording. It is possible that, for those without a GP referral date, the FHA may be an emergency hospital visit where diagnosis is made on that day. Another UK study also found that the median time from FHA to diagnosis was 0 days for lung cancer and for five other cancer types ([@bib1]) using patient survey data. As the same result was found using two different data sources, this suggests that many patients do receive their diagnosis at the FHA.

The high levels of missing data for stage, PS and co-morbidity were a weakness of the study and the inclusion of 'missing\' categories for these variables may result in bias. Multiple imputation was not possible as over 50% of the data were missing for these variables ([@bib37]). However, although a high proportion of missing data may make absolute estimates of proportions unreliable, it is unlikely to matter substantially for estimation of the independent effects of each variable, within each fully adjusted model. As the majority of other studies did not conduct multivariable analysis ([@bib29]), there is little other research to compare our results to, in order to assess whether missing data could account for any of the observed patterns. SEP was measured at an area-based level using IMD, which is a further limitation, as area-based measures may not accurately reflect individual-level circumstances.

Interpretation of results and comparison with other studies
-----------------------------------------------------------

### Diagnostic interval

Diagnostic delay has been implicated as a factor that contributes to the poorer survival of UK cancer patients compared with the European average ([@bib32]). However, the impact of delay on lung cancer survival is unclear ([@bib18]) and other studies suggest that those who experience shorter system delay may, in fact, have poorer lung cancer survival as they are at the 'sicker\' end of the spectrum ([@bib23]; [@bib13]), with symptoms that result in more urgent referral and diagnosis.

Two studies from Sweden ([@bib4]) and Denmark ([@bib8]), countries with similar healthcare systems to the United Kingdom, found socioeconomic inequalities in time from referral to diagnosis, with higher SEP patients having more prompt diagnosis. We found socioeconomic inequalities from GP referral to diagnosis and, within this interval, from GP referral to FHA, but not from FHA to diagnosis. This replicates previous UK findings ([@bib25]). The evidence therefore suggests that socioeconomic diagnostic inequalities are found in the GP referral to FHA interval rather than the secondary care FHA to diagnostic interval.

### Referral interval

It has been suggested that socioeconomic differences in communicating and presenting cancer symptoms to health professionals may result in longer delays for those who are less 'convincing\' ([@bib7]). Lower SEP patients may be less articulate, have poorer health literacy and be more culturally distant from doctors, whereas more educated cancer patients are better able to describe symptoms and thus speed up the referral process ([@bib16]; [@bib12]). However, a nonlinear trend in socioeconomic inequalities in the likelihood of being referred to secondary care within time interval guidelines was found. Those in the middle SEP groups were less likely to receive timely referral than those in the least deprived SEP group, but this was not seen for those in the most deprived SEP group.

The waiting time paradox suggests that sicker people are referred more quickly as they are more obviously ill, but also less likely to survive ([@bib34]), and so results in a positive association bias. Our findings of an inverse relationship between PS and likelihood of referral within target support this theory. This may be a possible explanation as to why the most deprived patients were not significantly less likely to receive a timely referral or diagnosis compared with the most affluent, as we might have expected. Patients with lower SEP had poorer PS (results not shown) and so were likely to be in generally poorer health. The results of this 'sicker quicker\' effect may, therefore, act to effectively 'cancel out\' any potential system inequalities that might result in longer referral and diagnosis intervals for more deprived patients.

In a previous study, age and sex did not appear to influence the likelihood of urgent referral for lung cancer ([@bib2]). We also found that sex was not associated with likelihood of timely referral and no clear pattern of referral was found by age.

Patients subsequently diagnosed with later-stage cancer and those with poor PS had a higher likelihood of being referred within 14 days. Stage, PS and co-morbidity score can all be considered as proxy measures for how ill a patient is, which may influence referral behaviour. Urgent referral requires the presence of 'alarm\' symptoms that are more likely to be present as the disease advances.

A previous small study found that co-morbidity delayed diagnosis in around 23% of lung cancer patients seen by GPs ([@bib5]). Symptoms (for example cough, weight loss or breathlessness) may be ascribed to a known co-morbidity (for example, COPD) rather than lung cancer. However, no clear-cut pattern was observed in referral or diagnosis time by co-morbidity score in this study, but those with poorer PS had increased likelihood of referral and diagnosis within target.

Both CCI score and PS can be used as proxy measures of general well-being and it is difficult to say how well they capture this ([@bib14]). CCI is a validated instrument for measuring co-morbidity ([@bib6]) but it is a fairly crude measure and, as it only contains details of conditions requiring in-patient care, it is likely to underestimate co-morbidity ([@bib15]). It may be that the number of co-morbidities is not a particularly sensitive measure of patient well-being and PS may be a better marker.

### Treatment interval

SEP was not associated with treatment within target from diagnosis. However, in the referral to treatment interval, those in the middle SEP groups appeared less likely to receive treatment within the 62-day guidelines, compared with the least deprived group. Those with SCLC, later-stage cancer and poorer PS were more likely to receive timely treatment within target. Again the 'sicker quicker\' phenomenon may explain this.

The previous evidence for time spent on the care pathway by age is mixed, with a UK study using patient survey data finding that younger patients had longer time intervals ([@bib25]). In agreement with a Swedish study using medical record data, which found that older patients had longer time to lung cancer treatment ([@bib21]), we also found that older patients were significantly less likely to receive treatment within target time. This was seen even when factors such as stage, co-morbidity and PS were taken into account, which might indicate that older patients are experiencing unwarranted delays.

### Implications for policy and practice, and further research

Due to changes in the way that date of diagnosis was calculated in 2010, it was difficult to be sure that any differences seen in this year were system changes as a result of the introduction of targets or just due to the change in rules for determining date of diagnosis. Consistent determination of GP referral, FHA, diagnosis and treatment dates and robust systems for reliably capturing this data are necessary for accurate calculation of referral, diagnosis and treatment intervals.

However, as improvements over time were found pre-2010, it does appear that introduction of NICE guideline targets ([@bib27]) has resulted in a greater proportion of patients being referred, diagnosed and treated within target times.

In this study, patients who underwent surgery as a first treatment were less likely to be treated within target compared with patients undergoing chemotherapy. It has been suggested that those who receive curative surgery may undergo a longer period of preliminary investigation with a greater number of diagnostic and staging procedures ([@bib10]). However, there may be capacity limitations on the pathway to surgery and future research should investigate whether it is possible to improve the timeliness of surgical treatment.

Older lung cancer patients were less likely to be treated within target times. Ageism in cancer care has been highlighted as an important problem that needs to be addressed ([@bib24]; [@bib20]) and our results add to the evidence for this. Clinicians need to ensure that older patients do not undergo unnecessary and unjustified delays in treatment. Research into the reasons for later treatment in older patients is required.

The patterns of results found in this study need to be clarified in other data sets, ideally with lower levels of missing stage, PS and co-morbidity data. Our findings suggest that more deprived patients are likely to appear more ill (as measured by PS) and the 'sicker quicker\' effect may neutralise any patient and system inequalities that might result in longer referral, diagnostic and treatment intervals for these patients, potentially relating to poorer communication and health literacy. Better evidence of inequalities in health literacy by SEP, and the role this may have in delay, is required. Investigation into patient and primary care delay before GP referral, and of inequalities within these intervals, is required.

Conclusions
===========

In this cohort, the main factor determining timely post-primary care referral, diagnosis and treatment for lung cancer was how sick patients appeared. Improvements in meeting NICE time interval targets were seen over time. However, older patients, who were more likely to have poor PS, were less likely to receive treatment within target, indicating possible age discrimination. It is possible that the 'sicker quicker\' effect may effectively 'cancel out\' system inequalities that might result in longer time intervals for more deprived patients.
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![**Intervals and target times on the cancer diagnosis and treatment pathway (adapted from [@bib16]).**](bjc2014472f1){#fig1}

###### Referral, diagnostic and treatment intervals

  **Interval**   **Definition of interval**                                                     **Target time (days)**
  -------------- ------------------------------------------------------------------------------ -------------------------------
  Referral       GP referral date to first hospital appointment date                            14
  Diagnostic     GP referral date to diagnosis date[a](#t1-fn2){ref-type="fn"}                  31[b](#t1-fn3){ref-type="fn"}
                 First hospital appointment date to diagnosis date[a](#t1-fn2){ref-type="fn"}   17[b](#t1-fn3){ref-type="fn"}
  Treatment      Diagnosis date to first treatment date                                         31
                 GP referral date to first treatment date                                       62

Abbreviation: GP=general practitioner.

Interim target intervals.

Calculated interim target times.

###### Post-primary care referral interval: likelihood of FHA within 14 days of GP referral[a](#t2-fn2){ref-type="fn"}

                        **GP** **referral & FHA date**   **FHA within 14 days of GP referral**   **Multivariable analysis (*****n*****=14 507,** ***R***^**2**^**=7.09)**[b](#t2-fn3){ref-type="fn"}                        
  --------------------- -------------------------------- --------------------------------------- ----------------------------------------------------------------------------------------------------- ------ ------ ------ ---------
  IMD                   14 507                           10 218                                  70.4                                                                                                                       0.0004
   1 (least deprived)   1709                             1263                                    73.9                                                                                                  1.00                  
   2                    2028                             1430                                    70.5                                                                                                  0.85   0.73   0.99    
   3                    2456                             1714                                    69.8                                                                                                  0.79   0.68   0.91    
   4                    3447                             2363                                    68.6                                                                                                  0.74   0.65   0.85    
   5 (most deprived)    4867                             3448                                    70.8                                                                                                  0.83   0.73   0.94    
  Age range             14 507                           10 218                                  70.4                                                                                                                       0.019
   \<60                 2008                             1450                                    72.2                                                                                                  1.00                  
   60--69               4143                             2975                                    71.8                                                                                                  0.97   0.86   1.10    
   70--79               5263                             3628                                    68.9                                                                                                  0.86   0.76   0.97    
   80+                  3093                             2165                                    70.0                                                                                                  0.89   0.77   1.02    
  Sex                   14 507                           10 218                                  70.4                                                                                                                       0.60
   Female               6601                             4681                                    70.9                                                                                                  1.00                  
   Male                 7906                             5537                                    70.0                                                                                                  1.02   0.95   1.10    
  Histology             14 507                           10 218                                  70.4                                                                                                                       \<0.001
   NSCLC                8803                             6077                                    69.0                                                                                                  1.00                  
   SCLC                 1898                             1479                                    77.9                                                                                                  1.64   1.45   1.85    
   Other                3806                             2662                                    69.9                                                                                                  1.03   0.94   1.13    
  Diagnosis year        14 507                           10 218                                  70.4                                                                                                                       \<0.001
   2006                 2465                             1235                                    50.1                                                                                                  1.00                  
   2007                 2575                             1475                                    57.3                                                                                                  1.34   1.20   1.50    
   2008                 3062                             2479                                    81.0                                                                                                  4.26   3.77   4.81    
   2009                 3156                             2501                                    79.3                                                                                                  4.39   3.79   5.09    
   2010                 3249                             2528                                    77.8                                                                                                  3.94   3.37   4.60    
  CCI score             14 507                           10 218                                  70.4                                                                                                                       \<0.001
   0                    1899                             1279                                    67.4                                                                                                  1.00                  
   1--2                 1389                             936                                     67.4                                                                                                  0.89   0.76   1.04    
   3+                   294                              201                                     68.4                                                                                                  0.80   0.60   1.05    
   Missing              5384                             3560                                    66.1                                                                                                  1.24   1.10   1.40    
   Unavailable          5541                             4242                                    76.6                                                                                                  0.96   0.83   1.10    
  Stage                 14 507                           10 218                                  70.4                                                                                                                       \<0.001
   I                    764                              504                                     66.0                                                                                                  1.00                  
   II                   393                              282                                     71.8                                                                                                  1.32   1.00   1.73    
   III                  1558                             1169                                    75.0                                                                                                  1.49   1.22   1.81    
   IV                   2307                             1848                                    80.1                                                                                                  1.77   1.47   2.15    
   Missing              9485                             6415                                    67.6                                                                                                  1.45   1.19   1.76    
  Performance status    14 507                           10 218                                  70.4                                                                                                                       0.001
   0                    1351                             990                                     73.3                                                                                                  1.00                  
   1--2                 3198                             2394                                    74.9                                                                                                  1.02   0.88   1.19    
   3--4                 1217                             988                                     81.2                                                                                                  1.36   1.11   1.67    
   Missing              8741                             5846                                    66.9                                                                                                  0.94   0.79   1.12    

Abbreviations: CCI score=Charlson co-morbidity score; CI=confidence interval; FHA=first hospital appointment; GP=general practitioner; IMD=Index of Multiple Deprivation; NSCLC=non-small-cell lung cancer; OR=odds ratio; SCLC=small-cell lung cancer.

Excluding those with FHA \>1 year from GP referral, diagnosis \>1 year from FHA, any negative time interval.

Mutually adjusted for socioeconomic position, age, sex, histology, year of diagnosis, co-morbidity score, stage and PS.

###### Diagnostic interval: likelihood of diagnosis within 31 days from GP referral, and of diagnosis within 17 days from FHA[a](#t3-fn2){ref-type="fn"}

                                             **GP referral to diagnosis**   **FHA to diagnosis**                                                                                       
  ------------------------------------------ ------------------------------ ---------------------- ------ ------ ------ ------ --------- -------- -------- ------ ------ ------ ------ ---------
  IMD                                        14 507                         11 978                 82.6                        0.08      27 555   25 197   91.4                        0.65
   1 (least deprived)                        1709                           1436                   84.0   1.00                           3257     2990     91.8   1.00                  
   2                                         2028                           1669                   82.3   0.90   0.75   1.07             4020     3666     91.2   0.91   0.77   1.09    
   3                                         2456                           2006                   81.7   0.84   0.71   1.00             4658     4239     91.0   0.88   0.75   1.04    
   4                                         3447                           2820                   81.8   0.83   0.71   0.97             6437     5887     91.5   0.90   0.77   1.05    
   5 (most deprived)                         4867                           4047                   83.2   0.94   0.80   1.09             9183     8415     91.6   0.93   0.80   1.08    
  Age range                                  14 507                         11 978                 82.6                        0.43      27 555   25 197   91.4                        0.89
   \<60                                      2008                           1661                   82.7   1.00                           3503     3166     90.4   1.00                  
   60--69                                    4143                           3437                   83.0   1.06   0.91   1.22             7262     6562     90.4   1.01   0.88   1.17    
   70--79                                    5263                           4314                   82.0   0.96   0.84   1.11             9830     8989     91.4   1.01   0.88   1.16    
   80+                                       3093                           2566                   83.0   0.97   0.83   1.15             6960     6480     93.1   0.96   0.82   1.13    
  Sex                                        14 507                         11 978                 82.6                        0.009     27 555   25 197   91.4                        0.03
   Female                                    6601                           5410                   82.0   1.00                           12 695   11 571   91.2   1.00                  
   Male                                      7906                           6568                   83.1   1.13   1.03   1.23             14 860   13 626   91.7   1.11   1.01   1.21    
  Histology                                  14 507                         11 978                 82.6                        \<0.001   27 555   25 197   91.4                        \<0.001
   NSCLC                                     8803                           7134                   81.0   1.00                           14 484   12 915   89.2   1.00                  
   SCLC                                      1898                           1674                   88.2   1.77   1.52   2.07             3350     3114     93.0   1.63   1.41   1.89    
   Other                                     3806                           3170                   83.3   1.06   0.94   1.19             9721     9168     94.3   1.45   1.29   1.64    
  Diagnosis year                             14 507                         11 978                 82.6                        \<0.001   27 555   25 197   91.4                        \<0.001
   2006                                      2465                           1895                   76.9   1.00                           5440     5082     93.4   1.00                  
   2007                                      2575                           2139                   83.1   1.49   1.29   1.71             5619     5298     94.3   1.16   0.99   1.35    
   2008                                      3062                           2706                   88.4   2.25   1.94   2.61             5541     5223     94.3   1.14   0.97   1.34    
   2009                                      3156                           2754                   87.3   2.41   2.03   2.87             5489     5111     93.1   1.13   0.95   1.36    
   2010                                      3249                           2484                   76.5   1.05   0.89   1.26             5466     4483     82.0   0.34   0.29   0.41    
  CCI score                                  14 507                         11 978                 82.6                        \<0.001   27 555   25 197   91.4                        \<0.001
   0                                         1899                           1527                   80.4   1.00                           3841     3492     90.9   1.00                  
   1--2                                      1389                           1102                   79.3   0.86   0.72   1.02             3377     3082     91.3   0.94   0.80   1.12    
   3+                                        294                            223                    75.9   0.68   0.50   0.92             886      798      90.1   0.84   0.65   1.08    
   Missing                                   5384                           4591                   85.3   1.53   1.32   1.77             9897     9367     94.6   1.54   1.33   1.80    
   Unavailable                               5541                           4535                   81.8   1.10   0.94   1.29             9554     8458     88.5   1.16   1.00   1.35    
  Stage                                      14 507                         11 978                 82.6                        \<0.001   27 555   25 197   91.4                        \<0.001
   I                                         764                            539                    70.6   1.00                           1116     879      78.8   1.00                  
   II                                        393                            304                    77.4   1.52   1.14   2.03             526      434      82.5   1.46   1.10   1.92    
   III                                       1558                           1313                   84.3   2.10   1.70   2.60             2172     1942     89.4   2.28   1.85   2.81    
   IV                                        2307                           2053                   89.0   2.91   2.36   3.60             3583     3340     93.2   3.30   2.68   4.06    
   Missing                                   9485                           7769                   81.9   1.63   1.32   2.02             20 158   18 602   92.3   1.71   1.39   2.11    
  Performance status                         14 507                         11 978                 82.6                        0.0007    27 555   25 197   91.4                        0.002
   0                                         1351                           1069                   79.1   1.00                           1759     1481     84.2   1.00                  
   1--2                                      3198                           2675                   83.7   1.22   1.03   1.44             4631     4107     88.7   1.17   0.99   1.39    
   3--4                                      1217                           1085                   89.2   1.66   1.30   2.12             2077     1952     94.0   1.44   1.13   1.83    
   Missing                                   8741                           7149                   81.8   1.18   0.97   1.44             19 088   17 657   92.5   1.43   1.17   1.73    
  Any treatment[d](#t3-fn5){ref-type="fn"}   14 507                         11 978                 82.6                        \<0.001   27 555   25 197   91.4                        \<0.001
   No                                        4974                           4241                   85.3   1.00                           12 863   12 228   95.1   1.00                  
   Yes                                       9533                           7737                   81.2   0.76   0.67   0.85             14 692   12 969   88.3   0.45   0.40   0.51    
  GP referral date                           14 507                         11 978                 82.6                                  27 555   25 197   91.4                        0.79
   No                                                                                                                                    13 048   12 105   92.8   1.00                  
   Yes                                                                                                                                   14 507   13 092   90.3   0.99   0.90   1.09    

Abbreviations: CCI score=Charlson co-morbidity score; CI=confidence interval; FHA=first hospital appointment; GP=general practitioner; IMD=Index of Multiple Deprivation; NSCLC=non-small-cell lung cancer; OR=odds ratio; SCLC=small-cell lung cancer.

Excluding those with FHA \>1 year from GP referral, diagnosis \>1 year from FHA, any negative time interval.

Mutually adjusted for socioeconomic position (SEP), age, sex, histology, year of diagnosis, co-morbidity score, stage and PS.

Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage, PS and GP referral date.

Within 1 year of diagnosis.

###### Treatment interval: likelihood of treatment within 31 days from diagnosis, and of treatment within 62 days from GP referral[a](#t4-fn2){ref-type="fn"}

                                               **Diagnosis to treatment**   **GP referral to treatment**                                                                                   
  -------------------------------------------- ---------------------------- ------------------------------ ------ ------ ------ ------ --------- ------ ------ ------ ------ ------ ------ ---------
  IMD                                          14 692                       6333                           43.1                        0.41      9542   5839   61.2                        0.04
   1 (least deprived)                          1844                         822                            44.6   1.00                           1186   760    64.1   1.00                  
   2                                           2207                         961                            43.5   0.97   0.84   1.10             1381   850    61.6   0.89   0.75   1.06    
   3                                           2493                         1060                           42.5   0.89   0.78   1.02             1611   969    60.2   0.83   0.70   0.97    
   4                                           3353                         1457                           43.5   0.94   0.83   1.07             2186   1310   59.9   0.79   0.68   0.92    
   5 (most deprived)                           4795                         2033                           42.4   0.91   0.81   1.03             3178   1950   61.4   0.88   0.75   1.01    
  Age range                                    14 692                       6333                           43.1                        \<0.001   9542   5839   61.2                        \<0.001
   \<60                                        2795                         1356                           48.5   1.00                           1749   1172   67.0   1.00                  
   60--69                                      5071                         2277                           44.9   0.90   0.81   0.99             3313   2105   63.5   0.93   0.81   1.05    
   70--79                                      5145                         2052                           39.9   0.75   0.68   0.83             3355   1913   57.0   0.73   0.64   0.83    
   80+                                         1681                         648                            38.6   0.79   0.69   0.91             1125   649    57.7   0.80   0.67   0.95    
  Sex                                          14 692                       6333                           43.1                        0.19      9542   5839   61.2                        0.11
   Female                                      6611                         2958                           44.7   1.00                           4260   2592   60.9   1.00                  
   Male                                        8081                         3375                           41.8   0.95   0.89   1.02             5282   3247   61.5   1.07   0.98   1.17    
  Histology                                    14 692                       6333                           43.1                        \<0.001   9542   5839   61.2                        \<0.001
   NSCLC                                       10 170                       3647                           35.9   1.00                           6864   3947   57.5   1.00                  
   SCLC                                        2499                         1863                           74.6   4.53   4.06   5.04             1554   1313   84.5   3.05   2.61   3.57    
   Other                                       2023                         823                            40.7   1.27   1.14   1.41             1124   579    51.5   0.87   0.76   0.99    
  Diagnosis year                               14 692                       6333                           43.1                        \<0.001   9542   5839   61.2                        0.14
   2006                                        2910                         1294                           44.5   1.00                           1659   965    58.2   1.00                  
   2007                                        2960                         1239                           41.9   0.89   0.80   0.99             1734   1020   58.8   1.02   0.88   1.18    
   2008                                        2870                         1035                           36.1   0.65   0.58   0.73             1967   1213   61.7   1.10   0.96   1.27    
   2009                                        3001                         1133                           37.8   0.71   0.62   0.83             2040   1258   61.7   1.17   0.97   1.41    
   2010                                        2951                         1632                           55.3   1.60   1.37   1.88             2142   1383   64.6   1.28   1.05   1.57    
  CCI score                                    14 692                       6333                           43.1                        0.45      9542   5839   61.2                        \<0.001
   0                                           2211                         914                            41.3   1.00                           1315   776    59.0   1.00                  
   1--2                                        1537                         580                            37.7   0.91   0.79   1.05             828    426    51.5   0.77   0.64   0.93    
   3+                                          330                          137                            41.5   1.07   0.83   1.37             147    74     50.3   0.72   0.50   1.03    
   Missing                                     5843                         2434                           41.7   1.01   0.90   1.13             3834   2363   61.6   1.12   0.97   1.30    
   Unavailable                                 4771                         2268                           47.5   1.03   0.90   1.17             3418   2200   64.4   1.11   0.94   1.32    
  Stage                                        14 692                       6333                           43.1                        \<0.001   9542   5839   61.2                        \<0.001
   I                                           870                          218                            25.1   1.00                           626    233    37.2   1.00                  
   II                                          384                          94                             24.5   0.86   0.65   1.15             314    136    43.3   1.09   0.82   1.45    
   III                                         1529                         567                            37.1   1.36   1.11   1.66             1176   756    64.3   1.61   1.29   2.00    
   IV                                          1909                         1024                           53.6   2.52   2.07   3.07             1366   1067   78.1   2.87   2.29   3.60    
   Missing                                     10 000                       4430                           44.3   1.82   1.49   2.22             6060   3647   60.2   1.65   1.32   2.07    
  Performance status                           14 692                       6333                           43.1                        0.0001    9542   5839   61.2                        0.02
   0                                           1599                         630                            39.4   1.00                           1247   750    60.1   1.00                  
   1--2                                        3417                         1502                           44.0   1.11   0.97   1.27             2476   1636   66.1   1.08   0.93   1.27    
   3--4                                        447                          247                            55.3   1.66   1.31   2.10             296    212    71.6   1.31   0.96   1.77    
   Missing                                     9229                         3954                           42.8   1.00   0.85   1.16             5523   3241   58.7   0.88   0.73   1.06    
  First treatment[d](#t4-fn5){ref-type="fn"}   14 692                       6333                           43.1                        \<0.001   9542   5839   61.2                        \<0.001
   Chemotherapy                                6587                         3470                           52.7   1.00                           4486   3273   73.0   1.00                  
   Surgery                                     2687                         864                            32.2   0.76   0.68   0.85             1748   654    37.4   0.37   0.32   0.42    
   Radiotherapy                                5418                         1999                           36.9   0.77   0.70   0.84             3308   1912   57.8   0.73   0.66   0.82    
  GP referral                                  14 692                       6333                           43.1                        \<0.001                                              
   No GP referral date                         5159                         2354                           45.6   1.00                                                                      
   FHA ⩽14 days                                6683                         2933                           43.9   0.92   0.85   1.00                                                        
   FHA \>14 days                               2850                         1046                           36.7   0.74   0.67   0.82                                                        

Abbreviations: CCI score=Charlson co-morbidity score; CI=confidence interval; FHA=first hospital appointment; GP=general practitioner; IMD=Index of Multiple Deprivation; NSCLC=non-small-cell lung cancer; OR=odds ratio; SCLC=small-cell lung cancer.

Excluding those with FHA \>1 year from GP referral, diagnosis \>1 year from FHA, any negative time interval.

Mutually adjusted for socioeconomic position (SEP), age, sex, histology, year of diagnosis, co-morbidity score, stage, PS and GP referral.

Mutually adjusted for SEP, age, sex, histology, year of diagnosis, co-morbidity score, stage and PS.

Within 1 year of diagnosis.
